VanEck Pharmaceutical ETF (PPH)
| Assets | $602.75M |
| Expense Ratio | 0.36% |
| PE Ratio | 21.97 |
| Shares Out | 6.54M |
| Dividend (ttm) | $1.54 |
| Dividend Yield | 1.69% |
| Ex-Dividend Date | Jul 1, 2024 |
| Payout Ratio | 37.09% |
| 1-Year Return | +17.01% |
| Volume | 147,176 |
| Open | 91.19 |
| Previous Close | 91.69 |
| Day's Range | 90.29 - 91.19 |
| 52-Week Low | 74.05 |
| 52-Week High | 93.44 |
| Beta | 0.48 |
| Holdings | 27 |
| Inception Date | Feb 1, 2000 |
About PPH
Fund Home PageThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.
Top 10 Holdings
64.65% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 13.38% |
| Novo Nordisk A/S | NVO | 10.30% |
| Johnson & Johnson | JNJ | 5.97% |
| Merck & Co., Inc. | MRK | 5.84% |
| AbbVie Inc. | ABBV | 5.49% |
| Novartis AG | NVS | 5.06% |
| AstraZeneca PLC | AZN | 4.88% |
| Sanofi | SNY | 4.61% |
| Pfizer Inc. | PFE | 4.60% |
| McKesson Corporation | MCK | 4.52% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jul 1, 2024 | $0.3558 | Jul 5, 2024 |
| Apr 1, 2024 | $0.5328 | Apr 5, 2024 |
| Dec 27, 2023 | $0.3074 | Dec 29, 2023 |
| Oct 2, 2023 | $0.3398 | Oct 6, 2023 |
| Jul 3, 2023 | $0.3891 | Jul 7, 2023 |
| Apr 3, 2023 | $0.6641 | Apr 10, 2023 |
News
Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.
Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.
Biotech Stocks Are Rallying, but the Outlook Isn't Good
The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.
Write A Prescription For This Pharma ETF
After scuffling amid political uncertainty leading up to Election Day, pharmaceutical stocks and exchange-traded funds are finally perking amid a spate of encouraging news regarding coronavirus vaccin...
A Divergence Has Occurred In Healthcare
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech.
3 ETFs in Focus as Race for Vaccine Intensifies
Several companies sit at the forefront of developing a coronavirus vaccine. Gain exposure to each using the following three ETFs.
Best Performing Pharmaceutical ETFs for Q3 2020
The best pharmaceutical ETFs for Q3 2020 are KURE, XPH, and PPH.